Metastatic and primary tumours are known to respond differently to chemotherapy. Therefore, when establishing drug efficacy it is important not to rely only on experiments in primary tumour models but to also study the test compound in metastasis models.
Organs can favour certain types of primary tumour cells and it is therefore highly important to test compounds in models that provide the correct microenvironment for metastases. Bone metastases, in particular, are a frequent source of pain for late-stage cancer patients and are often very resistant to treatment due to the characteristics of the bone. Compounds effectively treating or preventing bone metastases may also increase the overall survival.
To learn more about drug efficacy evaluation in bone metastasis models, including breast cancer models with MDA-MB-231, MCF-7, and BT-474 cells, prostate cancer moseld with PC-3 and LNCaP cells, and tumour detection parameters.